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Abstract: During the last years, proteomics has facilitated biomarker discovery by 
coupling high-throughput techniques with novel nanosensors. In the present review, we 
focus on the study of label-based and label-free detection systems, as well as 
nanotechnology approaches, indicating their advantages and applications in biomarker 
discovery. In addition, several disease biomarkers are shown in order to display the clinical 
importance of the improvement of sensitivity and selectivity by using nanoproteomics 
approaches as novel sensors.  
Keywords: biomarker; cancer; nanosensor; high-throughput techniques; microarray; 
proteomics 
 
1. Introduction  
Over the last decade, new-generation high-throughput (HT) methods have emerged and expanded in 
the field of proteomics, including next-generation sequencing and mass spectrometry technologies, 
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which have enabled the study of increasing amounts of proteins with less sample requirements. 
Overall, this has translated into the possibility of performing multi-level studies of human diseases 
from the perspectives of genomics, transcriptomics and proteomics [1]. 
Proteomics research in human pathology has focused on the development of clinical applications 
for accurate diagnosis, early detection and prognostic assessment of human disease due to its potential 
utility in the identification of candidate biomarkers associated to disease status. Noteworthy, the 
elucidation of drugs’ mechanisms of action by these approaches might lead to further characterization 
of new therapeutic targets. Hence, one of the most relevant applications of clinical proteomics is   
the identification and characterization of extremely-low abundance metabolites that might be   
disease-specific or even prognostic-associated. Therefore, the identification of biomarkers represents 
the ultimate tool for the improvement of early diagnostics, patient monitoring and for the evaluation of 
the safety and efficacy of therapeutic strategies [2,3]. 
Consequently the detection of such low-abundance biomarkers in biological fluids (e.g., blood, 
urine or saliva) requires HT detection techniques. In this sense, the integration of nanotechniques and 
proteomics has led to the development of nanoproteomics, which provides a robust analytical platform 
for real-time and sensitive detection of low-abundance proteins [4–6]. 
Therefore, nanoproteomics offers a real-time multiplexed analysis performed in a miniaturized 
assay, with low sample consumption and high sensitivity, thereby finding an increasing number of 
potential applications in research. Quantum dots, gold nanoparticles, carbon nanotubes and nanowires 
are few nanomaterials which have demonstrated potential to overcome the challenges of sensitivity 
faced by conventional proteomics for biomarker detection [7]. However, concerns regarding the 
toxicity and biocompatibility of nanotechniques still remain to be explored and much work is being 
carried out to ensure their safety for biological applications [8]. 
In this manuscript, we briefly describe the applications of nanoproteomics for biomarker discovery 
in various diseases focusing on neoplastic processes and also on auto-immune, metabolic and 
infectious diseases.  
2. Proteomics Technologies for Biomarker Discovery 
The advancement in proteomics techniques has provided a useful platform for the discovery of 
potential disease biomarkers, being protein microarrays one of the proteomics platforms involved jn 
biomarker discovery. Protein microarrays are miniaturized and parallelized array technology approaches 
for protein-protein interaction analysis and protein profiling [9,10]. Typically, thousands of proteins 
are printed and immobilized on functionalized glass slides, which can be simultaneously studied and 
analyzed in a HT fashion, thereby offering a high potential for characterizing the biology of a given 
cell of interest. To date, a number of microarray formats have been developed and recently implemented; 
all of them have tested as a versatile platform for many diverse applications [11]. Between them, there 
are DNA-microarrays or protein-chips which can use nanoporous alumina as substrate [12]. 
Together with the advances in microarray technologies, increasingly sensitive and reliable detection 
methodologies are being currently developed [4]. Such protein detection systems have progressively 
undergone a relevant transition from label-based to more sensitive label-free technologies.  S
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chromatography (LC or LC/LC) and analysis by tandem mass spectrometry (MS/MS); and (3) Data 
analysis including peptide/protein identification, quantification, and statistical analysis [22].  
The most common label-free techniques widely used in proteomics, briefly described, are:  
(i)  Relative quantification by peak intensity of LC-MS: based on the lineal correlation between the 
area of the peaks in the LC-MS and the protein concentration.  
(ii) Relative quantification by spectral count: in these methods, protein quantification is 
accomplished by comparing the number of identified MS/MS spectra from the same protein in 
each of the multiple LCMS/MS or LC/LC-MS/MS databases.  
(iii) Absolute  label-free  quantification:  it is used in the determination of absolute abundance 
proteins. This method gives the Protein Abundance Index (PAI), which is the number of 
identified peptides divided by the number of the theoretically observable tryptic peptides for 
each protein.  
In general, the label-free techniques are proved to be useful for the study of real-time kinetics of 
biomolecular interactions, which are not hindered by interaction with tag molecules.  
At present, there are many label-free detection strategies, such as surface plasmon resonance (SPR), 
CNTs, microelectromechanical cantilevers, surface-enhanced laser desorption ionization (SELDI)-time of 
flight (TOF)-MS, microfluidic purification chips (MPC), immunosensors based on channels of 
mesoporous silica (MPS), functionalized nanopipette probes, nanostructured electromechanical 
immunosensors featuring single-wall nanotubes (SWNT) forest and AuNPs [4,24–27]. Also, label-free 
protein-protein interactions were recently monitored using self-assembling protein arrays (named 
NAPPA microarrays) and atomic force microscopy (AFM), nanogravimetry, mass spectrometry and 
anodic porous alumina with the purpose of controlling the proteome alteration associated with cell 
proliferation, differentiation and neoplastic transformation [28–34]. 
Among other label-free techniques, SPR is a detection technique which analyzes molecular 
interactions onto a planar surface, based on the generation of surface plasmons (Figure 3). These are 
oscillations of free electrons that propagate in parallel to a metal/dielectric interface, which allow 
measuring changes in refractive index close to the sensor surface [35]. SPR enables accurate 
determination of kinetic parameters (association to dissociation rate) of the binding process between 
molecules as well as evaluate the strength of the binding and the specificity of the occurring 
interactions on large scale. As a consequence, it is possible to measure bimolecular interactions in  
real-time with a very high sensitivity [36]. 
Currently, SPR has been coupled with imaging to give the surface plasmon resonance imaging 
methods (SPRi). SPRi can analyze hundreds of samples on a single array. It is possible to use whatever 
biomolecule and the probe molecule is immobilized onto a metal coated slide (commonly a gold thin 
layer: <50 nm). This technique is also based on the formation of surface plasmons. The polarized light 
is reflected depending on the interactions on the array and is collected to give an image. Ladd et al. 
made use of SPRi techniques for the detection of candidate diagnostic biomarkers in cancer using 
antibody arrays. Interestingly, SPRi is showing to be a potential useful technique for biomarker 
characterization in serum proteomic studies [37]. Noteworthy, additional studies have been reported 
the combination of SPRi with a microfluidic chamber to obtain continuous flow of the analyte during 
the experiment.  Sensors 2012, 12  2290 
 
 
Finally, it is necessary to put emphasis on MPC, which was the first label-free system that used 
physiologic solutions, by detecting two biomarkers from a 10 µL sample of whole blood in less   
than 20 min [24]. 
Figure 3. Schematic description of Surface Plasmon Resonance. 
 
 
2.3. Nanotechnology in Proteomics 
Recently, there has been a great interest in applying nanomaterial-based electrochemical biosensors 
for the sensitive detection of biomolecules [38]. During the past few years, the potential of 
nanotechniques and nanomaterials in biomarker discovery has been studied [4,5]. Such emerging 
approaches are advantageous due to their high sensitivity, minimum sample requirements, accuracy, 
real-time sensing, and simplicity of the instruments, low cost and potential HT applications. In summary, 
nanotechniques offer several advantages with respect to classic proteomic techniques such as the 
miniaturization with a low amount of sample which leads to a higher sensibility and easier protocols.  
Nanoparticles show highly selective protein absorption and they can reach subcellular locations, 
which has a great impact on protein interactions and cellular behaviour.  
Among other nanomaterials, QDs, AuNPs, CNTs and silicon nanowires are promising candidates 
for biomarker detection and discovery. In addition, there are other promising nanotechniques which 
include microcantilevers (Figure 4), microfluidics, gold nanowires or silver nanomechanical   
resonators [8]. The technological aspects and working principles of commonly used nanoproteomics 
techniques for biomarker discovery have been discussed in detail in other reviews [4,5]. On the other 
hand, QDs, semiconductor nanocrystals, are applicable for labeling biomolecules and present Sensors 2012, 12  2291 
 
 
advantages compared with organic dyes [4], such as brighter fluorescence and photo-stability. Finally, 
CNTs have shown higher sensitivity than standard ELISA, providing detection limits superior to this 
classical technique [8]. 
Figure 4. Schematic description of microcantilevers detection systems used in biomarkers discovery. 
 
 
2.3.1. Gold Nanoparticles 
AuNPs can be modified with simple organic capping reagents or with high molecular weight 
biomolecules. Their unique optical properties, as well as their high thermal and electrical conductivity, 
make these materials valuable as components of biosensors, in vitro cell imaging and in vivo imaging 
and therapy [39]. 
Among metal nanoparticles, AuNPs have immense potential for cancer diagnosis and therapy on 
account of their SPR enhanced light scattering and absorption. AuNPs, which have to be labeled with 
accurate biomolecules, present a deviation in emission spectrum of scattered light because of effective 
binding of the analyte of interest from a protein sample by specific biomolecular interactions. This 
approach has been successfully used in PSA detection [40]. 
2.3.2. Quantum Dots 
QDs are semiconductors nanocrystals that exhibit unique electro-chemiluminiscent properties, 
strong light absorbance, bright fluorescence, size-tunable narrow emission spectra and provide 
excellent fluorescence quantum yields [4]. They are composed by elements from groups II–VI, III–V, 
or IV–VI of the periodic table, which can be attached to antibodies, aptamers, oligonucleotides, or 
peptides to be used to target cancer markers. These nanoparticles have many advantages such as their 
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low toxicity, their biocompatibility, high quantum yields, diverse surface modification flexibility and  
they are used with different wavelengths of emission allowing the concurrent analysis of multiple 
biomarkers [41]. 
QDs are applicable for labeling of biomolecules such as peptides, proteins or oligonucleotides and 
considered as an attractive alternative of traditional organic dyes [4]. They can be employed to 
quantify biomarkers in assays based on fluorescence resonance energy transfer (FRET) or as acceptors 
in bioluminescence resonance energy transfer (BRET). QDs are bound to different antibodies and can 
label HER-2, which over-expresses on some human breast cancer and is quantified through FRET  
in vitro assays. But also, they are used as contrast agents for in-vivo cancer imaging and detection, for 
example in prostate cancer [41]. 
These nanoparticles have been used as biological probes for the simultaneous detection of multiple 
biomarkers directly from biological components [42]. During past years, several groups have reported 
the use of QDs for detection of different types of cancers. QD-antibody conjugates are also well suited 
for the multiplexing capabilities of semiconductor QDs, enabled the authors to detect four protein 
biomarkers (CD15, CD30, CD45 and Pax5) of Hodgkin’s lymphoma from lymphoma tissues [8]. 
2.3.3. Carbon Nanotubes 
Electronic bio-detection methods are rapidly emerging in diagnostics due to the technological 
advantages associated with sensitivity, signal amplification, low sample consumption, detection time  
and multiplexing capacity. CNTs have a high potential as electronic biosensors owing to their intrinsic 
electrical, thermal and spectroscopic properties [43]. Hence, CNTs are rapidly being adapted in clinical 
research and have shown considerable promise in cancer diagnosis and therapy. Furthermore, they 
have shown higher sensitivity than standard ELISA, providing detection limits superior to this classical 
technique [8]. 
Malthotra  et al. constructed an electrochemical immunosensor using CNT arrays. They used 
secondary antibodies (HRP-labeled) for detection of low levels of IL-6 in experimental head and neck 
squamous cells carcionama cell lines [44]. CNTs have also been used as oxidase, dehydrogenase, 
peroxidase and catalase biosensors [45]. The use of CNT molecular wires offer great promise for 
achieving efficient electron transfer from electrode surfaces to the redox sites of enzymes. Better 
control of the chemical and physical properties of carbon nanotubes should lead to more efficient 
electrical sensing devices.  
2.3.4. Nanoparticle Biomarker Capture Technology 
Recently, a new strategy has been developed for the rapid detection of target protein biomarkers by 
MALDI-TOF mass spectrometry. The approach relies on selective sequestering of target proteins from 
complex media by engineered microgels, which select proteins by their size (<30 kDa) and isoelectric 
points (protein pI < 6.5). In this case, protein extraction is not necessary [46]. Also, smart hydrogel 
particles have been developed in order to detect biomarkers present at low concentrations. With this 
purpose, an affinity bait molecule has been introduced into N-isopropylacrylamide (NIPAm particles). 
This structure is capable of performing three independent functions within minutes, in one step, in Sensors 2012, 12  2293 
 
 
solution: (a) molecular size sieving; (b) affinity capture of all solution phase target molecules; and (c) 
complete protection of harvested proteins from enzymatic degradation [3,47]. 
2.3.5. Nanocomposite Matrices for Sensors 
Nanocomposite matrices, characterized by the presence of at least one component with two or three 
dimensions of less than 100 nanometers, are a mixture of inorganic, organic and biological materials. 
One recently described example is the mixture of cytochrome P450 with anodic porous alumina. In fact, a 
cytochrome P450 thin film developed and characterised in order to be used as cholesterol biosensor, is 
the most succesful inorganic biosensor based on P450ssc and anodic porous alumina, and will be 
explained in detail in the Biomarker Discovery in Metabolic Diseases section [29,48]. On the other 
hand, nanocomposites have been successfully employed as matrices suitable for protein microarrays. 
Nucleic Acid Programmable Protein Arrays (NAPPA) have been combined with anodic porous 
alumina (APA); and a few macromolecules have been successfully detected by this technique [48]. 
Nanocomposites have also been combined with multiwalled carbon nanotubes (MWNTs) providing 
a new material for conductometric acid vapours sensors [49]. In this way, carbon nanotubes can be 
introduced in conduction polymers, which allow biosensors with enhanced chemical and physical 
properties, and conduction polymers can be placed onto carbon nanotubes arrays [49]. 
3. Biomarker Discovery in Cancer 
As was described in the Introduction section, protein biomarkers (see Table 1) can be used to define 
a kind of cancer, the stage of the disease or select a treatment [3,50].  
Table 1. A list of cancer biomarkers detected by novel sensors based on nanoproteomics approaches. 
CANCER TUMOR  BIOMARKER DETECTION TECHNIQUES 
Breast cancer 
BRCA1, BRCA2  Protein Truncation Test (PTT) and western blotting 
C-MYC FISH 
CA 15.3, CEA, HER2/neu  Immunohistochemistry (ELISA) 
HER2/neu  Quantum dots (QD) and optofluidic ring resonator sensors 
CEA 
Gold nanoparticles based techniques, quantum dots (QD) and 
silicon photonic microring resonators 
Auto-antibodies against p53 or 
heat shock protein 60 and 90 (hsp) 
2D-PAGE, ELISA or NAPPA arrays 
Colorectal cancer 
CEA, CA 19.9, CA 72.4  Immunohistochemistry 
CEA 
Gold nanoparticles based techniques, quantum dots (QD) and 
silicon photonic microring resonators 
ANXA3, BMP4, LCN2, SPARC, 
MMP7, MMP11 
Immunoblotting and tissue microarray analysis 
Epithelial neoplasia  CEA, CYFRA 21-1  Immunohistochemistry 
Gastric cancer 
CEA, CA 19.9  Immunohistochemistry 
CEA 
Gold nanoparticles based techniques, quantum dots (QD) and 
silicon photonic microring resonators 
Germ cell tumor 
hCG, AFP, LDH  Immunohistochemistry 
AFP 
Gold nanoparticles based techniques, quantum dots (QD), 
carbon nanotubes (CNTs) Sensors 2012, 12  2294 
 
 
Table 1. Cont. 
CANCER  TUMOR BIOMARKER  DETECTION TECHNIQUES 
Head and neck cancer 
Desmoglein-3, Cytokeratin 4, 
Cytokeratin 16, Desmoplakin, 
Vimentin 
RPLC-MS/MS: MS-count of unique peptides per protein 
 
Keratin 4, Keratin 13, Cornulin, 
Small proline-rich protein 3 
2D DIGE 
 
14-3-3 sigma, 14-3-3 zeta/delta, 
hnRNPK, S100-A7, PTHA 
iTRAQ 
Hepatocarcinoma AFP 
Immunohistochemistry, gold nanoparticles based 
techniques, quantum dots (QD), carbon nanotubes (CNTs) 
 
Hsp27, Hsp70, and  
glucose-regulated protein 78 
2-DE and MS/MS 
Lung cancer  CA125  SELDI-TOF-MS 
 
HER2/neu, CYFRA 21-1, NSE, 
CEA 
Immunohistochemistry (ELISA) 
HER2/neu  Quantum dots (QD) and optofluidic ring resonator sensors 
 
CEA 
Gold nanoparticles based techniques, quantum dots (QD) 
and silicon photonic microring resonators 
Lymphoma LDH,  β2-microglobulin Immunohistochemistry  (ELISA) 
Myeloma Ig,  β2-microglobulin Immunohistochemistry  (ELISA) 
Ovarian cancer  CA-125  SELDI-TOF-MS 
HER2/neu  Quantum dots (QD) and optofluidic ring resonator sensors 
 
LDH, CA 15.3, HER2/neu, CEA, 
CA 19.9 
Immunohistochemistry 
 
CEA 
Gold nanoparticles based techniques, quantum dots (QD) 
and silicon photonic microring resonators 
 
Tropomyosin family, actin family, 
triosephosphate isomerase family, 
Hsp60 
Peptide fragment matching and MS/MS 
Pancreatic cancer  CA 19.9, CA 72.4, MUC1  Immunohistochemistry (ELISA) 
Papillary and 
follicular thyroid 
carcinoma 
Thyroglobulin  Immunohistochemistry and PCR-RT 
Prostate cancer 
PSA 
Gold nanoparticles based techniques, quantum dots (QD), 
carbon nanotubes (CNTs), silicon nanowires and 2D 
cantilever array chip 
PAP, PG, urinary calgranulin 
B/MRP-14 
2-DE MALDI-TOF-MS 
Prostate cancer-24 protein  SELDI-MS 
HER2/neu  Quantum dots (QD) and optofluidic ring resonator sensors 
Testicular cancer 
AFP 
Gold nanoparticles based techniques, quantum dots (QD), 
carbon nanotubes (CNTs) 
β-hCG Immunohistochemistry 
Trophoblastic disease  Gonadotropin  Immunohistochemistry  
 
Because of modern life style factors (sedentarism, nutritional habits, environmental contamination 
or life expectancy) some cancers are more prevalent, why it is necessary to find new biomarkers of the Sensors 2012, 12  2295 
 
 
early stages to have more possibilities of earlier diagnostic of cancers [3,51]. Extracellular matrix 
proteins and elements secreted by a tumor can be diagnostic biomarker candidates. Secreted proteins 
are responsible for cell communication, so translating these signals into information could provide 
knowledge of the molecular mechanisms of neoplasia [51]. Also, modifications in glycosylation and 
the carbohydrate structure of proteins have been associated to cancer [52]. 
In the case of prostate cancer, Prostate Specific Antigen (PSA) is the biomarker usually used in the 
diagnostic of this pathology. PSA appears preferentially in the prostate, but it is produced by other 
tissues. Although it is a substance which is found in prostate, in patients it is localized at low 
concentrations in blood which are measured to make the diagnosis and the prognostics of cancer [51]. 
However, it is well known that PSA is not a biomarker as specific as it is necessary because the 
increase in PSA levels detected by 2D electrophoresis (2-DE) MALDI-TOF MS or SELDI 
Quadrupole-TOF (SELDI-qTOF) (Figure 3(A)) can be due to the age or prostatitis [52]. For this 
reason new biomarkers are needed [51]. 
Both prostatic acid phosphatase (PAP) and progastricsin (PG), which are overexpressed in prostate 
carcinoma, have been detected by 2-DE MALDI-TOF-MS. This technique has also identified a new 
potential biomarker: urinary calgranulin B/MRP-14. SELDI-MS has allowed detecting prostate   
cancer-24 protein, which appeared in 94% of prostate carcinomas and does not in normal cells. One of 
the most interesting lines which are being recently studied is likely biomarkers in prostatasomes, 
membranous vesicles secreted by the prostatic gland whose function is related with sperm motility and 
protection against female immunity in fecundation. Although more than 440 prostatasomes proteins 
have been recognized and categorized by LC-Electrospray ionisation/Mass Spectrometry (LC-ESIMS/MS) 
coupled with a gas phase fractionation (GPF), it is too soon to propose some new biomarkers. Also, 
metabolomics have identified a huge number of metabolites as potential biomarkers such as sarcosine, 
which is likely to indicate the progression to metastasis [52]. 
Breast cancer is the most prevalent cancer in women and the first cause of death, mostly because of 
the distant metastases. For this reason, it is necessary to identify the early stage biomarkers [51]. The 
lack of serum biomarkers drives to a too late detection of cancer, when surgery is no longer possible 
and/or metastasis processes are presented. An early detection might be possible only through both 
invasive and non-invasive techniques. Nowadays, a premature diagnosis is achieved by regular 
mammographies [53]. 
In breast cancer, many different mutations have been found, most of them in proto-oncogenes 
and/or tumor suppressor genes such as BRCA1, BRCA2, HER2-neu, C-MYC, and Cyclin D-1. As a 
result, auto-antibodies have been detected against the mutated genes such as p53 or heat shock protein 
60 and 90 (hsp). 2D-PAGE, ELISA or NAPPA arrays have been some of the technologies used to try 
to detect breast cancer auto-antibodies. However, antibodies are not likely to be accurate biomarkers, 
unless they are into account together [53]. 
The most widely used serum marker in breast cancer diagnostics is CA 15-3, which is a soluble 
form of the mucin MUC1, which is in turn a marker of breast cancer. MUC1 is usually placed in the 
apical membrane of normal secretory epithelium, when malignant transformation has happened, 
MUC1 is translocated to the external plasmatic membrane, where is susceptible of suffering proteolytic 
cleavage. As a result, it is found as a soluble antigen which is usually detected by immunoassays. Sensors 2012, 12  2296 
 
 
Unfortunately, as MUC1 changes its glycosylation pattern during neoplastic transformation, so it 
cannot be used as an early breast cancer biomarker [53]. 
In connection with glycoprotein and cancer, in breast cancer as in so many others, there are 
alterations in glycoproteins. The most known example is the Human Epidermal Growth Factor 
Receptor 2 (HER2/neu), which is a trans-membrane glycoprotein and whose overexpression means the 
malignant transformation of the tumor [53]. 
Ovarian cancer, one of the most aggressive and lethal cancers in women, lacks of a non-invasive 
diagnostic exam in order to detect it in the earliest stages [51]. Comparing samples from patients with 
ovarian cancer and healthy individuals, it was found that CA125 had the sensitivity of 60.7% and the 
specificity of 55% for distinguishing ovarian cancer from non-cancer samples. Moreover, four proteins 
were found, which are better biomarkers than CA125, using SELDI-TOF-MS protein chip technology; 
which is widely used to monitor the patients after the chemotherapy [54]. 
Pancreatic ductal adenocarcinoma (PDAC) is another of the most aggressive cancers and the 
problem lies in the fast metastasis [51]. This cancer has the worst prognosis and the mortality 
percentage is very similar to the rate of incidence. The best biomarker in pancreatic cancer is CA 19-9, 
which is a sialylated Lewis antigen of the MUC1 protein and is detected by serum immunoassay [55]. 
Although sensitivity is about an 80% and specificity about 90%, this biomarker also appears in some 
diseases such as cirrhosis or chronic pancreatitis. That is why it cannot be used as an accurate 
biomarker. Most of the pancreatic cancers are discovered by computed tomography (CT) or magnetic 
resonance imaging [56]. 
Other kinds of cancer, for example colorectal or lung cancer, are not related with specific and 
accurate biomarkers because of problems such as low concentration or the masking by other proteins. 
Colorectal cancer is one of the most insidious cancers. The preferential treatment is surgery after  
neo-adjuvant treatment, but in most of cases metastases reappear some years later. Although 
biomarkers for metastasis are not known, researchers are making an effort to discover them. Lung 
cancer is the most prevalent and the major cause of death worldwide nowadays. Melanoma is a lower 
incidence dermatological cancer, but it is responsible of 80% of skin cancer death because of its fast 
metastasis to the brain [51]. 
4. Biomarker Discovery in Autoimmune Diseases 
The importance of the detection of biomarkers for autoimmune diseases (see Table 2) lies in the 
need of an early detection of diseases, as well as the disease progression to disability and the response 
to therapy [57]. Autoimmune diseases appear in 3% of the population and until, now the diagnosis is 
made through clinical examination, laboratory tests and imaging techniques. Since last decade, 
biomarkers for diagnostic of immune diseases employing different proteomics approaches have been 
studied [58]. 
A specific characteristic of this disease is the presence of autoantibodies in systemic circulation as 
well as in specific proximal fluids and tissues. The main problem appears as a consequence of the 
immunity against self-molecules, auto-antigens, which can be related with the alterations on the gene 
which regulate the self-tolerance paths [57]. Proteomics allow the study of the key events which 
happen in the protein level such as post-translational modifications or antibody production [57]. Sensors 2012, 12  2297 
 
 
Table 2. A list of autoimmune biomarkers detected by novel sensors based on 
nanoproteomics approaches.  
AUTOINMUNE DISEASE  AUTOINMUNE BIOMARKER DETECTION  TECHNIQUES 
Diabetes has  Magnetic  relaxation  nanosensors 
Behcet’s disease 
α-tropomyosin  IEC, SDS-PAGE and ESI-MS (sera) 
Selenium-binding protein  2-DE and immunoblot (sera) 
α- enolase, Haptoglobin  2-DE and MALDI-TOF-MS (sera) 
Serum amyloid A  2-DE and MALDI-TOF/TOF-MS (sera) 
Juvenile idiopathic arthritis 
Transferrin, ceruloplasmin,  
Serum amyloid A 
Chromatographic protein chips,  
SELDI-TOF-MS (sera/urine). 
Serotransferin, GAPDH,  
α-1 anti-trypsin 
IP of CIC's, 2DE, ESI-MS/MS (serum) 
Citrulinated fibrinogen,  
complement 3, complement 1q 
IP of CIC's, SEC/LC, ESI-MS (serum) 
Complement 3c, apolipoprotein 
AII,vitamin D binding protein 
DIGE, MALDI-TOF/TOF 
(plasma, synovial fluid) 
Type 1 diabetes  GDC glutamate decarboxylase  Supramolecular protein nanoparticles 
Rheumatoid arthritis 
Cyclic citrulline peptide 
ELISA and Peptide-coated nanotube-based 
biosensor 
peptides of C-reactive protein 
(PCR) 
SDS-PAGE and triple quadrupole (TQ)-MS  
by multiple-reaction monitoring (MRM) 
p38 MAPK  Flow cytometry and Western blotting 
RF ELISA 
Wegener Granulomatosis  PR3  Carbon nanotubes as multicolor Raman labels 
In rheumatoid arthritis (RA), a systemic inflammatory disease related with alterations in human 
leukocyte antigen (HLA)-DRB1 locus, it has been necessary to find accurate biomarkers which 
identify the early stages of the disease, before cartilage damage ocurrs [59].  
Diverse proteomic technologies have contributed to the discovery of biomarkers in autoimmune 
diseases, such as: (i) 2-DE and MS for auto-antigen discovery; (ii) autoantigen microarrays to typify 
autoantibody responses; (iii) antibody array technologies to profile cytokines and other biomolecules; 
(iv) reverse-phase protein arrays to analyze phosphoproteins; (v) flow cytometric analysis of 
phosphoproteins [57,60].  
For example, Zhen and colleagues have developed microarrays which consist of putative and 
candidate genes printed by a robot over the array and probed against immune or control serum. The 
potential interaction is detected by fluorophore-conjugated anti-human secondary antibodies and they 
have found that the appearance of citrulline in RA means more severe disease and the detection of 
native and unmodified peptides is associated with mild disease [61]. 
Western blotting has allowed identifying some post-translational modifications variants of proteins 
have been characterized as auto-antigens such as citrullinated alpha-enolase in RA [57]. 
However, traditional MS or array-based proteomic assays face several limitations in the detection of 
multiple low abundance biomarkers from complex biological samples under clinically relevant 
conditions due to their sensitivity and specificity issues. Moreover, the detection process is very slow Sensors 2012, 12  2298 
 
 
and it is often characterized by an unsuitable screening of large numbers of samples. These challenges 
of proteomics techniques prompted researcherd to apply different nanotechniques for biomarker 
discovery in auto-immune diseases.  
Peptide-coated nanotubed are one of the recent approaches for the development of new 
immunosensors for diseases with specific serological autoantibodies, such as RA. Drouvalakis et al. 
determined cyclic citruline from patient serum in fentomolar (fM) range [62]. 
Wegener´s granulomatosis is a rare auto-immune disease coupled with anti-neutrophil antibodies, 
which affect blood vessels as well as various other organs. Proteinase 3 (PR3) is a potential serum 
biomarker for this autoimmune disease and is used for routine diagnosis of the disease. Although it is 
difficult to detect such a low abundance protein in complex samples, Chen and collaborators have 
developed a nanoproteomics approach for detection, at 1 fM level, of the target molecule by using 
antibodies conjugated with Raman tags for selective detection of PR3 [63]. In this case, the sensitivity 
which has been shown is higher than conventional fluorescence-based protein microarrays and 
traditional ELISA assays.  
Biomarkers for systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), both autoimmune 
connective tissue diseases, can be found using recombinant antibody microarrays. Carlsson and 
collaborators have developed a system in order to target mainly immunoregulatory proteins present in 
these autoimmune diseases. In this way, they found differentiation biomarkers between SLE and SSc. 
They also, observed differences increased with severity of SLE; thus, IL-2, IL-12 and IFN-γ were 
detected [64]. Hence, proteomics has shown to be a great candidate to detect disease biomarkers and 
control the phenotypic subsets and activity of diseases. 
5. Biomarker Discovery in Infectious Diseases 
Besides various cancers and autoimmune diseases, serum proteome analysis has also been tested for 
many infectious diseases such as tuberculosis, leprosy and hepatitis, among others [65,66].  
Infectious diseases have become the leading cause of death in developing countries. That is one of 
the reasons why biomarkers (see Table 3) to achieve detection kits are needed [67]. New tools can help 
to identify the pathogen, evaluate the illness severity or establish the best treatment. Although lateral 
flow immunoassays, ELISA and the polymerase chain reaction (PCR) have been used with their 
limitations in the developed countries, these techniques frequently cannot be used in the developing 
countries. The World Health Organization has established the accurate characteristics to the diagnostic 
devices in the developing countries. They are summarized in the ASSURED criteria: A for Affordable, 
S for Sensitive, S for Specific, U for User-Friendly, R for Robust and Rapid, E for Equipment-Free and 
D for Deliverable to those who need them [68]. 
Among the potential biomarkers are products and targets with immunological memory of a 
pathogen, molecules which allow differentiating between infected and healthy individuals as well as 
assays, which recognize pathogen proteins and molecules. Until now, the main techniques used to 
detect the infectious individuals were serology and molecular methods. Although work on proteomic 
approaches is going on, the use of biomarkers will depend on our understanding of each infectious 
disease immunopathogenesis [67]. Sensors 2012, 12  2299 
 
 
Table 3. A list of infectious biomarkers detected by novel sensors based on 
nanoproteomics approaches. 
INFECTIOUS DISEASE  INFECTIOUS BIOMARKER DETECTION TECHNIQUES 
Anthrax  Anthrax protective antigen  Europium nanoparticlebased immunoassay 
Anthrax  Bacillus anthracis Protective antigen  Multichannel waveguides 
Candidiasis  D-arabinitol  One step electrodeposition 
Chronic liver diseases, cirrhosis 
and hepatocellular carcinoma 
Hepatitis B and C virus antibodies  Nano-gold immunological amplification on 
protein chip 
Diptheria  Diphtheria antigen  Potentiometric immunosensor 
Food borne disease  Listeria monocytogenes  Bioconjugated silica nanoparticles probe  
with FITC 
Food borne illness  Salmonella  Bioconjugated nanoparticles 
Gonorrhea  Neisseria gonorrhoeae  Nano-structure zinc oxide film 
Hepatitis B  HBV virus  Microfluidic device with microbead array  
and QD 
HIV-1 Infection  HIV-1 p24 antigen  Nanoparticlebased immunoassay 
HIV-1 p24 Gag protein  Nanoparticle-based bio-barcode 
amplification 
Parasitic disease  Schistosoma japonicum antibody  Silver-enhanced colloidal gold 
metalloimmunoassay 
Salmonellosis  Salmonella typhimurium antigen  Hybrid electrochemical/magnetic assay 
Tuberculosis  Protein amyloid A, transthyretin  Surface-enhanced laser desorption 
ionization time of flight (SELDI-TOF) 
mass spectrometry 
Agranoff and collaborators made use of SELDI-TOF-MS for identification of 20 most discriminatory 
proteins by comparing serum profiles from 179 tuberculosis subjects [69]. By MALDI-TOF-MS, both 
proteins amyloid A and transthyretin were demonstrated as potential serum biomarkers for early 
diagnosis of tuberculosis.  
Another study identified differentially expressed proteins by MALDI-TOF and MALDI-TOF-MS/MS 
of leprosy patients and healthy individuals [70]. A significant increase in one of the isoforms of 2α 
chain of haptoglobin was determined in leprosy patients.  
During the last years, several nanoproteomics studies have been conducted to study different types 
of infectious diseases. Tang et al. have demonstrated the selective detection of anthrax protective 
antigen from serum samples using a novel sensing approach based on europium nanoparticle-based 
immunoassay. This novel approach offered 100-fold enhancement in detection limit (0.01 ng/mL) as 
compared to the traditional colorimetric development reagents of ELISA assays [71].  
Another recently described approach allows the detection of dengue virus infection, based on a 
combination of integrated microfluidic system and magnetic beads. The designed strategy reaches high 
sensitivity levels (21 pg) in a 30 min assay, indicating the potential of such sensing strategies for the 
development of rapid diagnostic test in infectious diseases [72]. 
Over the last two decades, anti-retroviral therapy (ART) has been successfully used reducing the 
morbidity and mortality of HIV-1. However, many patients have developed several immune 
abnormalities and their risk to suffer non-AIDS associated diseases has increased. Owing to that, it is Sensors 2012, 12  2300 
 
 
necessary to find biomarkers which allow classifying patients into groups at risk of suffering non-
AIDS diseases. HIV infected patients are also increasingly susceptible to suffering opportunistic 
pathogen infections, which is termed as immune restoration disease (IRD). One of the most frequent 
and severe IRDs is tuberculosis (TB). Usually, this combination highly increases the worsening of the 
pathology, particularly, the progression of extrapulmonary disease and lymphadenitis. Oliver and Price 
found in 2011 that CCL2 chemokine shows a decrease in its levels when a patient submitted to ART is 
going to develop TB [67,73]. 
Prion diseases, such as Creutzfeldt-Jacob (CJD), are neurodegenerative diseases related to the 
transformation of the normal host cellular prion protein (PrP
c) into the abnormal protease-resistant 
isoform (PrP
Sc). The traditional diagnosis is based on the detection of proteinase K resistant, misfolded 
form (PrPSc) of cellular prion protein in the central nervous system (CNS). Biomarkers are needed to 
detect the disease in the early stages to avoid the progression of the disease over time. Sanchez et al. 
found a 13.4 KDa protein in cerebrospinal fluid (CSF), which was analyzed by cationic exchange 
chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and   
LC-MS/MS and it was revealed that the protein was cystatin C [74]. This protein had been found by 
other researchers, also in blood, and it is known that its increase in CJD affected patients is related with 
the disease. Mabbott et al. have found dendritic cells and macrophages carrying PrP
Sc. Macrophages 
may even transport the abnormal protein in the absence of Follicular Dendritic Cells (FDCs) that is 
why the authors have considered the possibility that macrophages are a new structure in prion 
accumulation. On the other hand, dendritic cells can spread the infection towards other parts of   
the body [75]. 
6. Biomarker Discovery in Metabolic Diseases 
Serum profiling has also provided biomarkers (see Table 4) for many other human diseases such as 
non-alcoholic fatty liver disease, diabetes, ischemic and hemorrhagic stroke [76]. Here, some of them 
are listed: 
(i) Glucose biosensor: glucose levels can be monitored either in vivo or in vitro. Nowadays, there 
are biosensors based on conducting polymers, which have been shown to be useful for glucose 
estimation form 1 to 40 mM and a stability of about 6 days. A novel glucose biosensor based on 
MWNTs have been developed improving upon the previous ones [29]. 
(ii) Lactate biosensor: until now, two different technologies have been approached for the 
development of nanosystems: film electrodes in combination with microdialysis systems and screen 
printed electrodes, which have shown a linear dynamic range from 0.2 to 1 mM of lactate and a 
stability of about 3 weeks. 
(iii) Urea and creatinine biosensors: most of them are based on detection of NH4
+ or HCO3
− 
sensitive electrodes. A composite film of electropolymerized inactive polypyrrole and a poly ion 
complex has been developed.  
(iv) Cholesterol biosensor: the measurement of cholesterol is based on an amperometric biosensor. 
This sensor responds even in presence of potential electrical interferences, as L-ascorbic acid, pyruvic 
acid and uric acid. The most successful cholesterol biosensor, recently described, is the one based on 
the P450-linked side chain cleaving enzyme (P450ssc), which consists of P450 cytochrome and Sensors 2012, 12  2301 
 
 
adrenadoxin, a P450 reductant, and it has been used to make an amperometric biosensor to detect and 
measure the LDL-cholesterol in liquid solution. It is based on the Anodic Porous Alumina (APA), 
which is a specific size porous matrix, and in the organic poly-cationic poly-L-Lysine (PLL), which 
allows a molecular anchorage as well as a direct electron transfer. The APA layer is placed onto a 
rhodium–graphite screen-printed electrode (s.p.e.) and the P450ssc was immobilized through the PLL. 
The enzyme and analyte binding leads to a redox reaction, which can be translated into an electrical 
signal producing a direct electron transfer between the enzyme and the electrode. The cholesterol 
detection and measurement is made by cyclic voltammetry (CV). It is achieved a very good stability 
mainly because the enzyme was very strongly trapped in the APA/PLL matrix [29,48]. 
(v) Uric acid biosensor: useful in gout, hyperuricaemia and Lesch-Nyhan syndrome. 
Table 4. A list of metabolic biomarkers detected by novel sensors based on nanoproteomics approaches. 
METABOLIC DISEASE  METABOLIC BIOMARKER DETECTION  TECHNIQUES 
Diabetes mellitus 
Glucose 
Glucose sensors: electrostatic layer-by-layer (LBL) 
nanoassembly of capsules composed of multi-layers 
of polymer films, standard enzymatic 
electrochemical and nanomaterial-based sensors 
Extracellular glutathione 
peroxidase, apo-lipoprotein E 
Spectrophotometry and electrochemical techniques 
Gout Uric  acid Spectrophotometry  and electrochemical techniques 
Hyperuricaemia Uric  acid  Spectrophotometry and electrochemical techniques 
Lesch-Nyhan syndrome  Uric acid  Spectrophotometry and electrochemical techniques 
Chronic liver diseases 
Fibrinogen B chain, 
paraoxonase 1, prothrombin, 
serum amyloid P component 
Immunohistochemistry 
Heart fatty acid-binding protein has been identified as a novel diagnostic serum biomarker for 
earlier diagnostic of stroke using a gel-based proteomic approach.  
Serum proteomics have been also found to be a good alternative to liver biopsy for detection of 
common chronic liver diseases like non-alcoholic fatty liver disease. Recently, it has been described 
fibrinogen B chain, paraoxonase 1, prothrombin and serum amyloid P component as novel serum 
biomarkers [65] using a LC-MS/MS approach [76]. 
In 2007 Kim et al. identified extracellular glutathione peroxidase and apo-lipoprotein E as potential 
serum biomarkers using 2D ESI-qTOF MS/MS approach, and verified their results by Western blotting 
and ELISA in diabetes mellitus patients. This represents an alternative to conventional finger-prick 
capillary blood glucose self-monitoring, which has several disadvantages: it is painful, it cannot be 
performed when the patient is sleeping or doing some activity and it is intermittent, which means it can 
miss dangerous fluctuations in blood glucose concentrations between tests. For all these reasons, the 
ideal blood glucose monitoring would therefore be continuous and non-invasive [77]. 
Measurement problems in diabetes can be solved with nano-approaches, such as biocompatible 
nanofilms, glucose nanosensors, quantum dots or gold nanoparticles [78]. 
The detection of glucose levels used as diabetes biomarker, can be made through encapsulation  
of glucose sensors that could be implanted in the body avoiding degradation and denaturation Sensors 2012, 12  2302 
 
 
maintaining, at the same time, glucose access and detectable signal change. This kind of encapsulation 
can be carried out by the electrostatic layer-by-layer (LBL) nanoassembly of capsules composed of 
multi-layers of polymer films [78]. Also, nanotechnology has increased the surface area of sensors. So 
far, sensors in diabetes are based on electrochemical enzymatic measurements with screenprinted 
eletrodes. However, nanotechnology can offer higher surface area/volume ratios as well as enhanced 
optical properties (QDs, AuNPs, SERS) allowing improvements in accuracy, size, lifetime and 
usability of sensors for the treatment of diabetes [79]. 
The principal strategy used in diabetes is based on standard enzymatic electrochemical detection of 
glucose. In this way, we can use CNTs, nanowire arrays fabricated from ruthenium and gold, which 
increase surface area and improve electrochemical detection. On the other hand, nanomaterials allow 
the development of direct oxidation glucose sensors as replacements to biological recognition sensors. 
For this purpose, it can be used porous films, nanorods and nanoparticles composed of silver, gold, 
nickel and nickel/palladium. 
It is also possible to design nanomaterial-based sensors to detect glucose through changes in pH or 
charge, such as field effect transitor (FET), which seems to be a good option. Finally, for in vivo 
continuous monitoring, fluorescence-based sensors offer several advantages. In this case, sensors 
would be implanted into the skin of the patient. They would have to be replaced weekly or monthly 
because of problems with signal degradation, however with this strategy, it is not necessary to take 
blood samples [79]. 
During the last decade, emerging nanotechniques have been using for biomarkers detection in 
metabolic diseases. Lin et al. have reported simultaneous label-free electrochemical detection of two 
cardiovascular biomarker proteins, CRP and myeloperoxidase directly in human serum. In this 
nanoproteomics approach, high-density nanowells were prepared on top of each electrode using 
nanoporous silica membrane to improve sensitivity and selectivity (down to 1 pg/mL) [26].  
7. Concluding Remarks 
Proteomics research has revealed many novel disease biomarkers by applying various top-down and 
bottom-up approaches including gel-based techniques, MS, affinity separation and microarrays. 
Technological working aspects of different conventional proteomics techniques have been described in 
other reviews.  
Despite the immense progress, biomarker discovery is still facing several biological and 
technological challenges such as the wide dynamic range of protein concentrations, difficulty of 
detection of low-abundance proteins and extreme variations between individuals.  
During the last years, nanotechniques have undergone a significant progress for reliable handling 
the complexity of the cell proteome. Therefore a number of nanotechniques have been lately used for 
diverse applications such as biomarker discovery, label-free protein detection, study protein-protein 
interactions and printing protein microarrays. The advantages offered by these approaches have 
allowed to be successfully coupled with the rapidly expanding field of proteomics. Among other 
relevant emerging techniques, CNTs, QDs or AuNPs have drawn great attention due to their potential 
to minimize sample and reagent consumption.  Sensors 2012, 12  2303 
 
 
However, nanotechniques still face several limitations to be resolved for widespread application  
in biomarker discovery. Currently, new proteomics and nanotechnology disciplines are being 
progressively adopted by clinical researchers due to the availability of multiple-novel techniques and 
all the potential applications to deep into the knowledge of the pathophysiology of unresolved diseases. 
All the methodologies and techniques briefly described in this minireview, might eventually lead to the 
characterization of new molecular entities and/or disease-associated molecular modifications for 
improving diagnostic and prognostic stratification. Despite this, many efforts are still required to 
implement the current status of these approaches towards clinical standardization. 
Nowadays, it is possible to anticipate a significant development in the near future that will make  
nano-proteomics for biomarkers discovery field more robust, sensitive, reliable and above all, 
biocompatible and environmentally friendly.  
Acknowledgments 
We gratefully acknowledge financial support from the Carlos III Health Institute of Spain (ISCIII, 
FIS PI081884) and JCYL-SAN10. María González-González is supported by a ISCIII FIS08/00721 
PhD scholarship. Sara Paradinas is supported by a JCYL-EDU/1468/2008 PhD scholarship. 
References  
1.  Wong, S.C.; Chan, C.M.; Ma, B.B.; Lam, M.Y.; Choi, G.C.; Au, T.C.; Chan, A.S.; Chan, A.T. 
Advanced proteomic technologies for cancer biomarker discovery. Expert Rev. Proteomics 2009, 
6, 123–134.  
2.  Madu, C.O.; Lu, Y. Novel diagnostic biomarkers for prostate cancer. J. Cancer 2010, 1, 150–177.  
3.  Rakowska, P.D.; Ryadnov, M.G. Nano-enabled biomarker discovery and detection. Biomark. 
Med. 2011, 5, 387–396.  
4.  Gonzalez-Gonzalez, M.; Jara-Acevedo, R.; Matarraz, S.; Jara-Acevedo, M.; Paradinas, S.; 
Sayagues, J.M.; Orfao, A.; Fuentes, M. Nanotechniques in proteomics: Protein microarrays and 
novel detection platforms. Eur. J. Pharm. Sci. 2011, 45, 499–506.  
5.  Matarraz, S.; Gonzalez-Gonzalez, M.; Jara, M.; Orfao, A.; Fuentes, M. New Technologies in 
cancer. Protein microarrays for biomarker discovery. Clin. Transl. Oncol. 2011, 13, 156–161.  
6.  Xia, H.; Murray, K.; Soper, S.; Feng, J. Ultra sensitive affinity chromatography on   
avidin-functionalized PMMA microchip for low abundant post-translational modified protein 
enrichment. Biomed. Microdevices 2011, doi: 10.1007/s10544-011-9586-7. 
7.  Chandra, H.; Reddy, P.J.; Srivastava, S. Protein microarrays and novel detection platforms. 
Expert Rev. Proteomics 2011, 8, 61–79.  
8.  Ray, S.; Reddy, P.J.; Choudhary, S.; Raghu, D.; Srivastava, S. Emerging nanoproteomics 
approaches for disease biomarker detection: A current perspective. J. Proteomics 2011,  74,  
2660–2681.  
9.  Tomizaki, K.Y.; Usui, K.; Mihara, H. Protein-protein interactions and selection: Array-based 
techniques for screening disease-associated biomarkers in predictive/early diagnosis. FEBS J. 
2010, 277, 1996–2005.  Sensors 2012, 12  2304 
 
 
10.  LaBaer, J.; Ramachandran, N. Protein microarrays as tools for functional proteomics. Curr. Opin. 
Chem. Biol. 2005, 9, 14–19.  
11.  Hu, Y.; Uttamchandani, M.; Yao, S.Q. Microarray: A versatile platform for high-throughput 
functional proteomics. Comb. Chem. High Throughput Screen. 2006, 9, 203–212.  
12.  Grasso, V.; Lambertini, V.; Ghisellini, P.; Valerio, F.; Stura, E.; Perlo, P.; Nicolini, N. 
Nanostructuring of a porous alumina matrix for a biomolecular microarray. Nanotechnology 2006, 
17, 795–798.  
13.  Collings, F.B.; Vaidya, V.S. Novel technologies for the discovery and quantitation of biomarkers 
of toxicity. Toxicology 2008, 245, 167–174. 
14.  Meany, D.L.; Zhang, Z.; Sokoll, L.J.; Zhang, H.; Chan, D.W. Glycoproteomics for prostate cancer 
detection: Changes in serum PSA glycosylation patterns. J. Proteome Res. 2009, 8, 613–619.  
15.  Srivastava, M.; Eidelman, O.; Jozwik, C.; Paweletz, C.; Huang, W.; Zeitlin, P.L.; Pollard, H.B. 
Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol. Genet. 
Metab. 2006, 87, 303–310.  
16.  Zhou, H.; Bouwman, K.; Schotanus, M.; Verweij, C.; Marrero, J.A.; Dillon, D.; Costa, J.;   
Lizardi, P.; Haab, B.B. Two-color, rolling-circle amplification on antibody microarrays for 
sensitive, multiplexed serum-protein measurements. Genome Biol. 2004, 5, R28.  
17.  Wu, W.; Slastad, H.; de la Rosa Carrillo, D.; Frey, T.; Tjonnfjord, G.; Boretti, E.; Aasheim, H.C.; 
Horejsi, V.; Lund-Johansen, F. Antibody array analysis with label-based detection and resolution 
of protein size. Mol. Cell. Proteomics 2009, 8, 245–257.  
18.  Blazer, L.L.; Roman, D.L.; Muxlow, M.R.; Neubig, R.R. Use of flow cytometric methods to quantify 
protein-protein interactions. Curr. Protoc. Cytom 2010, doi: 10.1002/0471142956.cy1311s51.  
19.  Harsha, H.C.; Molina, H.; Pandey, A. Quantitative proteomics using stable isotope labeling with 
amino acids in cell culture. Nat. Protoc. 2008, 3, 505–516.  
20.  Everley, P.A.; Krijgsveld, J.; Zetter, B.R.; Gygi, S.P. Quantitative cancer proteomics: Stable 
isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. 
Mol. Cell. Proteomics 2004, 3, 729–735.  
21.  Waanders, L.F.; Hanke, S.; Mann, M. Top-down quantitation and characterization of   
SILAC-labeled proteins. J. Am. Soc. Mass Spectrom. 2007, 18, 2058–2064.  
22.  Zhu, W.; Smith, J.W.; Huang, C.M. Mass spectrometry-based label-free quantitative proteomics. 
J. Biomed. Biotechnol. 2010, doi: 10.1155/2010/840518.  
23.  Kodoyianni, V. Label-free analysis of biomolecular interactions using SPR imaging. 
BioTechniques 2011, 50, 32–40.  
24.  Stern, E.; Vacic, A.; Rajan, N.K.; Criscione, J.M.; Park, J.; Ilic, B.R.; Mooney, D.J.; Reed, M.A.; 
Fahmy, T.M. Label-free biomarker detection from whole blood. Nat. Nanotechnol. 2010, 5, 138–142.  
25.  Umehara, S.; Karhanek, M.; Davis, R.W.; Pourmand, N. Label-free biosensing with 
functionalized nanopipette probes. Proc. Natl. Acad. Sci. USA 2009, 106, 4611–4616.  
26.  Lin, J.; Wei, Z.; Mao, C. A label-free immunosensor based on modified mesoporous silica for 
simultaneous determination of tumor markers. Biosens. Bioelectron. 2011, 29, 40–45.  
27.  Chikkaveeraiah, B.V.; Mani, V.; Patel, V.; Gutkind, J.S.; Rusling, J.F. Microfluidic 
electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in 
serum. Biosens. Bioelectron. 2011, 26, 4477–4483.  Sensors 2012, 12  2305 
 
 
28.  Nicolini, C.; Pechkova, E. Nanoproteomics for nanomedicine. Nanomedicine (Lond.) 2010, 5, 
677–682.  
29.  Nicolini, C.; Sivozhelezov, V.; Bavastrello, V.; Bezzerra, T.; Scudieri, D.; Spera, R.; Pechkova, E. 
Matrices for sensors from inorganic, organic, and biological nanocomposites. Materials 2011, 4, 
1483–1518.  
30.  Maccioni, E.; Radicchi, G.; Erokhin, V.; Paddeu, S.; Facci, P.; Nicolini, C. Bacteriorhodopsin thin 
film as a sensitive layer for an anaesthetic sensor. Thin Solid Films 1996, 284–285, 898–900. 
31.  Paternolli, C.; Ghisellini, P.; Nicolini, C. Nanostructuring of heme-proteins for biodevice 
applications. IET Nanobiotechnol. 2007, 1, 22–26.  
32.  Paternolli, C.; Neebe, M.; Stura, E.; Barbieri, F.; Ghisellini, P.; Hampp, N.; Nicolini, C. 
Photoreversibility and photostability in films of octopus rhodopsin isolated from octopus 
photoreceptor membranes. J. Biomed. Mater. Res. A 2009, 88, 947–951.  
33.  Nicolini, C.; Pechkova, E. An overview of nanotechnology-based functional proteomics for 
cancer and cell cycle progression. Anticancer Res. 2010, 30, 2073–2080.  
34.  Nicolini, C.; LaBaer, J. Functional Proteomics & Nanotechnology-Based Microarrays; Pan 
Stanford Series on Nanobiotechnology: Singapore, 2010; Volume 2, Chapters 1–12, pp. 1–347. 
35.  Ramachandran, N.; Larson, D.N.; Stark, P.R.; Hainsworth, E.; LaBaer, J. Emerging tools for   
real-time label-free detection of interactions on functional protein microarrays. FEBS J. 2005, 
272, 5412–5425.  
36.  Torreri, P.; Ceccarini, M.; Macioce, P.; Petrucci, T.C. Biomolecular interactions by surface 
plasmon resonance technology. Ann. Ist. Super. Sanita 2005, 41, 437–441.  
37.  Ladd, J.; Taylor, A.D.; Piliarik, M.; Homola, J.; Jiang, S. Label-free detection of cancer biomarker 
candidates using surface plasmon resonance imaging. Anal. Bioanal. Chem. 2009, 393, 1157–1163.  
38.  Zhang, X.; Guo, Q.; Cui, D. Recent advances in nanotechnology applied to biosensors. Sensors 
2009, 9, 1033–1053. 
39.  Zahavy, E.; Whitesell, J.K.; Fox, M.A. Surface effects in water-soluble shell-core hybrid gold 
nanoparticles in oligonucleotide single strand recognition for sequence-specific bioactivation. 
Langmuir 2010, 26, 16442–16446.  
40.  Bao, Y.P.; Wei, T.F.; Lefebvre, P.A.; An, H.; He, L.; Kunkel, G.T.; Muller, U.R. Detection of 
protein analytes via nanoparticle-based bio bar code technology. Anal. Chem. 2006, 78, 2055–2059.  
41.  Wagner, M.K.; Li, F.; Li, J.; Li, X.F.; Le, X.C. Use of quantum dots in the development of assays 
for cancer biomarkers. Anal. Bioanal Chem. 2010, 397, 3213–3224.  
42.  Yezhelyev, M.V. In situ molecular profiling of breast cancer biomarkers with multicolor quantum 
dots. Adv. Mater. 2007, 19, 3146–3151. 
43.  Sinha, N.; Yeow, J.T.-W. Carbon nanotubes for biomedical applications. IEE Trans. Nanobiosci. 
2005, 4, 180–195. 
44.  Malhotra, R.; Patel, V.; Vaque, J.P.; Gutkind, J.S.; Rusling, J.F. Ultrasensitive electrochemical 
immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and 
multilabel amplification. Anal. Chem. 2010, 82, 3118–3123.  
45.  Wang, J. Carbon-nanotube based electrochemical biosensors: A review. Electroanalysis 2005, 17, 
7–14. Sensors 2012, 12  2306 
 
 
46.  Cerasoli, E.; Rakowska, P.D.; Horgan, A.; Ravi, J.; Bradley, M.; Vincent, B.; Ryadnov, M.G. 
MiS-MALDI: Microgel-selected detection of protein biomarkers by MALDI-ToF mass 
spectrometry. Mol. Biosyst. 2010, 6, 2214–2217.  
47.  Luchini, A.; Geho, D.H.; Bishop, B.; Tran, D.; Xia, C.; Dufour, R.L.; Jones, C.D.; Espina, V.; 
Patanarut, A.; Zhou, W.; et al. Smart hydrogel particles: Biomarker harvesting: One-step affinity 
purification, size exclusion, and protection against degradation. Nano Lett. 2008, 8, 350–361.  
48.  Stura, E.; Bruzzese, D.; Valerio, F.; Grasso, V.; Perlo, P.; Nicolini, C. Anodic porous alumina as 
mechanical stability enhancer for LDL-cholesterol sensitive electrodes. Biosens. Bioelectron. 
2007, 23, 655–660.  
49.  Bavastrello, V.; Stura, E.; Carrara, S.; Erokhin, V.; Nicolini, C. Poly(2,5-dimethylaniline)-MWNTs 
nanocomposite: A new material for conductometric acid vapours sensor. Sens. Actuat. B Chem. 
2004, 98, 247–253.  
50.  Jokerst, J.V.; Raamanathan, A.; Christodoulides, N.; Floriano, P.N.; Pollard, A.A.; Simmons, G.W.; 
Wong, J.; Gage, C.; Furmaga, W.B.; Redding, S.W.; et al. Nano-bio-chips for high performance 
multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using 
quantum dot bioconjugate labels. Biosens. Bioelectron. 2009, 24, 3622–3629.  
51.  Makridakis, M.; Vlahou, A. Secretome proteomics for discovery of cancer biomarkers.   
J. Proteomics 2010, 73, 2291–2305.  
52.  Goo, Y.A.; Goodlett, D.R. Advances in proteomic prostate cancer biomarker discovery.   
J. Proteomics 2010, 73, 1839–1850.  
53.  Misek, D.E.; Kim, E.H. Protein biomarkers for the early detection of breast cancer. Int. J. 
Proteomics 2011, doi: 10.1155/2011/343582.  
54.  Zhang, H.; Kong, B.; Qu, X.; Jia, L.; Deng, B.; Yang, Q. Biomarker discovery for ovarian cancer 
using SELDI-TOF-MS. Gynecol. Oncol. 2006, 102, 61–66.  
55.  Gold, D.V.; Modrak, D.E.; Ying, Z.; Cardillo, T.M.; Sharkey, R.M.; Goldenberg, D.M. New 
MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J. Clin. Oncol. 
2006, 24, 252–258.  
56.  Buxbaum, J.L.; Eloubeidi, M.A. Molecular and clinical markers of pancreas cancer. JOP 2010, 
11, 536–544.  
57.  Hueber, W.; Robinson, W.H. Proteomic biomarkers for autoimmune disease. Proteomics 2006, 6, 
4100–4105.  
58.  Krenn, V.; Petersen, I.; Haupl, T.; Koepenik, A.; Blind, C.; Dietel, M.; Konthur, Z.; Skriner, K. 
Array technology and proteomics in autoimmune diseases. Pathol. Res. Pract. 2004, 200, 95–103.  
59.  Pinto, J.A.; Rego, I.; Rodriguez-Gomez, M.; Canete, J.D.; Fernandez-Lopez, C.; Freire, M.; 
Fernandez-Sueiro, J.L.; Sanmarti, R.; Blanco, F.J. Polymorphisms in genes encoding tumor 
necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients 
with rheumatoid arthritis. J. Rheumatol. 2008, 35, 177–178.  
60.  Lee, S.; Serada, S.; Fujimoto, M.; Naka, T. Application of Novel Quantitative Proteomic 
Technologies to Identify New Serological Biomarkers in Autoimmune Diseases. Available online: 
http://www.intechopen.com/source/pdfs/20669/InTechApplication_of_novel_quantitative_proteo
mic_technologies_to_identify_new_serological_biomarkers_in_autoimmune_diseases.pdf (accessed 
on 1 December 2011). Sensors 2012, 12  2307 
 
 
61.  Li, Q.Z.; Xie, C.; Wu, T.; Mackay, M.; Aranow, C.; Putterman, C.; Mohan, C. Identification of 
autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.  
J. Clin. Invest. 2005, 115, 3428–3439.  
62.  Drouvalakis, K.A.; Bangsaruntip, S.; Hueber, W.; Kozar, L.G.; Utz, P.J.; Dai, H. Peptide-coated 
nanotube-based biosensor for the detection of disease-specific autoantibodies in human serum. 
Biosens. Bioelectron. 2008, 23, 1413–1421.  
63.  Chen, Z.; Tabakman, S.M.; Goodwin, A.P.; Kattah, M.G.; Daranciang, D.; Wang, X.; Zhang, G.; 
Li, X.; Liu, Z.; Utz, P.J.; et al. Protein microarrays with carbon nanotubes as multicolor raman 
labels. Nat. Biotechnol. 2008, 26, 1285–1292.  
64.  Carlsson, A.; Wuttge, D.M.; Ingvarsson, J.; Bengtsson, A.A.; Sturfelt, G.; Borrebaeck, C.A.; 
Wingren, C. Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using 
recombinant antibody microarrays. Mol. Cell. Proteomics 2011, doi: 10.1074/mcp.M110.005033.  
65.  Bell, C.; Smith, G.T.; Sweredoski, M.J.; Hess, S. Characterization of the mycobacterium 
tuberculosis proteome by liquid chromatography mass spectrometry-based proteomics techniques: 
A comprehensive resource for tuberculosis research. J. Proteome Res. 2012, 11, 119–130.  
66.  Liu, T.; Xue, R.; Huang, X.; Zhang, D.; Dong, L.; Wu, H.; Shen, X. Proteomic profiling of 
hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted Laser 
desorption/ionization time-of-flight mass spectrometry. Acta Biochim. Biophys. Sin. (Shanghai) 
2011, 43, 542–550.  
67.  Gaudieri, S. Biomarkers that reflect immune activation or dysfunction will be important in the 
management of infectious diseases. Biomark. Med. 2011, 5, 109–112.  
68.  Hauck, T.S.; Giri, S.; Gao, Y.; Chan, W.C. Nanotechnology diagnostics for infectious diseases 
prevalent in developing countries. Adv. Drug Deliv. Rev. 2010, 62, 438–448.  
69.  Agranoff, D.; Fernandez-Reyes, D.; Papadopoulos, M.C.; Rojas, S.A.; Herbster, M.; Loosemore, A.; 
Tarelli, E.; Sheldon, J.; Schwenk, A.; Pollok, R.; et al. Identification of diagnostic markers for 
tuberculosis by proteomic fingerprinting of serum. Lancet 2006, 368, 1012–1021.  
70.  Gupta, N.; Shankernarayan, N.P.; Dharmalingam, K. Alpha1-acid glycoprotein as a putative 
biomarker for monitoring the development of the type II reactional stage of leprosy. J. Med. 
Microbiol. 2010, 59, 400–407.  
71.  Tang, S.; Moayeri, M.; Chen, Z.; Harma, H.; Zhao, J.; Hu, H.; Purcell, R.H.; Leppla, S.H.; 
Hewlett, I.K. Detection of anthrax toxin by an ultrasensitive immunoassay using europium 
nanoparticles. Clin. Vaccine Immunol. 2009, 16, 408–413.  
72.  Lee, Y.F.; Lien, K.Y.; Lei, H.Y.; Lee, G.B. An integrated microfluidic system for rapid diagnosis 
of dengue virus infection. Biosens. Bioelectron. 2009, 25, 745–752.  
73.  Oliver, B.G.; Price, P. The search for biomarkers of immune restoration disease associated with 
mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. Biomark. Med. 
2011, 5, 149–154.  
74.  Sanchez, J.C.; Guillaume, E.; Lescuyer, P.; Allard, L.; Carrette, O.; Scherl, A.; Burgess, J.; 
Corthals, G.L.; Burkhard, P.R.; Hochstrasser, D.F. Cystatin C as a potential cerebrospinal fluid 
marker for the diagnosis of creutzfeldt-jakob disease. Proteomics 2004, 4, 2229–2233.  
75.  Mabbott, N.A.; Mackay, F.; Minns, F.; Bruce, M.E. Temporary inactivation of follicular dendritic 
cells delays neuroinvasion of scrapie. Nat. Med. 2000, 6, 719–720.  Sensors 2012, 12  2308 
 
 
76.  Ray, S.; Reddy, P.J.; Jain, R.; Gollapalli, K.; Moiyadi, A.; Srivastava, S. Proteomic technologies 
for the identification of disease biomarkers in serum: Advances and challenges ahead. Proteomics 
2011, 11, 2139–2161.  
77.  Kim, H.J.; Cho, E.H.; Yoo, J.H.; Kim, P.K.; Shin, J.S.; Kim, M.R.; Kim, C.W. Proteome analysis 
of serum from type 2 diabetics with nephropathy. J. Proteome Res. 2007, 6, 735–743.  
78.  Pickup, J.C.; Zhi, Z.L.; Khan, F.; Saxl, T.; Birch, D.J. Nanomedicine and its potential in diabetes 
research and practice. Diabetes Metab. Res. Rev. 2008, 24, 604–610.  
79.  Cash, K.J.; Clark, H.A. Nanosensors and nanomaterials for monitoring glucose in diabetes. 
Trends Mol. Med. 2010, 16, 584–593.  
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 